GlucoTrack, Inc. enters the final day of April with one of the most extreme short setups in the small-cap health care space — a 27% weekly rally, a short interest near 32% of the free float, and a cost to borrow sitting above 400%.
The lending market tells the clearest story here. Short sellers are paying a punishing rate to stay in position — cost to borrow is running at 420% annualised, up roughly 23% over the past month. That is not a temporary spike. The rate has held above 400% for most of April, and traded as high as 528% in early April. Availability has tightened significantly alongside the borrow cost. The borrow pool was almost entirely consumed as recently as mid-April, when the 52-week peak utilisation of 99.8% was recorded. The current reading of ~80% means roughly one share available for every four already borrowed — still a tight market. Shorts that need to establish or maintain positions face a high and sustained carry cost.
Short interest itself has been volatile and difficult to read this week. At 31.6% of the free float as of Wednesday, the level is deeply elevated — but the intraday path has been erratic, swinging from under 2% on April 24 back above 31% on April 29. The official FINRA fortnightly report, settled April 15, put short shares at 670,479. The daily estimate now tracks slightly below that, at around 564,000 shares. The ORTEX short score jumped to 80.8 on April 29, up from 46 on April 24, reflecting the sudden reassembly of short interest after what appears to have been a brief but sharp covering event mid-week. That covering likely contributed to the stock's 27% weekly gain, closing Wednesday at $0.92.
The earnings history adds an uncomfortable layer of context for both sides. All three recent earnings-related events have been negative for the stock on the day: a 34% one-day drop in March, a 15% drop in April, and a 10% drop in March. The five-day reactions have also been negative, ranging from -14% to -18%, with the single exception of a November 2025 event that produced a +37% five-day move. No next earnings date is currently flagged, but the pattern of sharp post-event declines is consistent with a stock where the news cycle regularly disappoints.
Correlated peers have had a rough week. OBIO, MBOT, ARAY, STSS, and CODX all fell between 8% and 10% over the same period that GCTK gained 27%. The divergence suggests GCTK's move was short-covering driven rather than sector-wide sentiment improving. Institutional ownership is thin. Armistice Capital holds around 5% of shares, Ikarian Capital 2.4%, and total disclosed holders number just 15. The insider trade data is stale — the last recorded transaction was in April 2024 — so ownership provides little near-term signal.
The setup going into next week is straightforward to describe: shorts are paying over 400% to borrow a stock that just rallied sharply, short interest remains near a third of the float, and the borrow market remains tight. Whether the covering pressure that drove this week's bounce has fully resolved — or whether fresh short positions re-entered at higher levels — is the question the short score's abrupt jump back to 80 on April 29 poses most directly.
See the live data behind this article on ORTEX.
Open GCTK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
